Efficacy and safety of JAK inhibitors for vitiligo: an updated systematic review and meta-analysis of randomized controlled trials.
J Dermatolog TreatAug 28, 2026 (epub)
Clinical ResearchDermatology
Ziyi Lin, Yi Chen, Jingpeng Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of JAK inhibitors for vitiligo, analyzing nine randomized controlled trials with 1826 patients. JAK inhibitors significantly increased the F-VASI75 response compared to placebo (RR 4.59, 95% CI 3.20-6.59; p < 0.001). The findings suggest that JAK inhibitors are effective and well tolerated.
Key findings
- JAK inhibitors increased F-VASI75 versus placebo (RR 4.59, 95% CI 3.20-6.59; p < 0.001).
- For F-VASI50, JAK inhibitors were superior to tacrolimus (RR 1.88, 95% CI 1.02-3.45).
- Serious adverse events were comparable between JAK inhibitors and other treatments (RR 1.15, 95% CI 0.57-2.33).
Why it matters
The findings support the use of JAK inhibitors as an effective treatment for vitiligo, particularly in patients with limited facial disease. Understanding their efficacy and safety profile can guide clinicians in treatment decisions.